Market access & investment

Commercial and funding perspectives

Content addressing market access strategy and investment activity in advanced therapies, including views relevant to companies preparing for commercialisation and to investors assessing the sector.

Video interviews and written pieces feature perspectives from executives and researchers connected to the Cell & Gene Therapy World and Phacilitate events.

The resource library brings together a wide range of materials created for professionals working across the cell and gene therapy field. Visitors can find reports, ebooks, videos and interviews drawn from leading event communities, each addressing the practical challenges that arise when moving advanced therapies from research through to commercial readiness. Topics are organised around the themes that consistently shape strategic conversations, including manufacturing approaches, supply chain design, market access planning and investment considerations, helping teams build a clearer picture of the landscape they are operating within.

Within this collection, a content library serves as a working reference for groups evaluating manufacturing, logistics and commercial strategy. It is designed to support day-to-day decision making rather than to act as a static archive, offering perspectives that reflect the pace of change across the advanced therapies sector. Teams can return to it as new questions emerge around scaling production, managing distribution complexity or preparing for later stage reimbursement discussions, making the library a flexible companion throughout the life cycle of a therapy programme.

The accompanying blog provides ongoing articles and commentary from writers close to the event community. Posts track developments across regenerative medicine, immuno-oncology, stem cell research and other adjacent areas, translating technical progress into language that is accessible to both scientific and business audiences. By following the blog, readers can stay connected to the broader conversation shaping conferences, advisory boards and training opportunities, while also picking up signals about where attention and investment are likely to focus next.

Alongside these written resources, a dedicated automation report examines the growing role of automated systems in cell and gene therapy manufacturing. It looks at how automation is being applied to reduce manual variability, support reproducible processes and improve overall operational efficiency, while also considering the organisational changes that come with adopting these technologies. Together, the reports, blog and supporting media form a curated resource hub intended to help leaders in the field make informed, forward looking decisions.